Genmab A/S Profit Margin

Genmab A/S (GNMSF) currently reports a profit margin of 8.98% as of September 2026. That compares with 52.48% in the prior-year period — down 82.9% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore Genmab A/S's profit margin history and peer comparisons.

Genmab A/S's profit margin decreased from 52.48% to 8.98% — a 82.9% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Genmab A/S's profit margin of 8.98% is lower than the Healthcare sector average of 19.13%. That is roughly 53.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Genmab A/S's current 8.98% should be judged against Healthcare norms (sector average: 19.13%) and against GNMSF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 8.98%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Genmab A/S, and consider following GNMSF for alerts when major investors trade the stock.